- Home
- ONCO vs RDHL Comparison
ONCO vs RDHL Comparison
Compare ONCO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- RDHL
- Stock Information
- Founded
- ONCO 2018
- RDHL 2009
- Country
- ONCO United States
- RDHL Israel
- Employees
- ONCO N/A
- RDHL N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- RDHL Health Care
- Exchange
- ONCO Nasdaq
- RDHL Nasdaq
- Market Cap
- ONCO 4.3M
- RDHL 3.9M
- IPO Year
- ONCO 2022
- RDHL N/A
- Fundamental
- Price
- ONCO $2.21
- RDHL $1.03
- Analyst Decision
- ONCO
- RDHL
- Analyst Count
- ONCO 0
- RDHL 0
- Target Price
- ONCO N/A
- RDHL N/A
- AVG Volume (30 Days)
- ONCO 28.9K
- RDHL 1.5M
- Earning Date
- ONCO 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- ONCO N/A
- RDHL N/A
- EPS Growth
- ONCO N/A
- RDHL N/A
- EPS
- ONCO N/A
- RDHL N/A
- Revenue
- ONCO $1,223,751.00
- RDHL $9,550,000.00
- Revenue This Year
- ONCO N/A
- RDHL $381.91
- Revenue Next Year
- ONCO N/A
- RDHL N/A
- P/E Ratio
- ONCO N/A
- RDHL N/A
- Revenue Growth
- ONCO N/A
- RDHL 157.62
- 52 Week Low
- ONCO $2.10
- RDHL $1.01
- 52 Week High
- ONCO $179.35
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- ONCO 33.70
- RDHL 33.58
- Support Level
- ONCO $2.17
- RDHL $1.01
- Resistance Level
- ONCO $2.53
- RDHL $1.07
- Average True Range (ATR)
- ONCO 0.20
- RDHL 0.09
- MACD
- ONCO -0.05
- RDHL 0.01
- Stochastic Oscillator
- ONCO 16.01
- RDHL 7.58
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.